Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Yi-Ke Guo"'
Autor:
Jia-Shiuan Ju, Allen Chung-Cheng Huang, Pi-Hung Tung, Chi-Hsien Huang, Tzu-Hsuan Chiu, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation is brain metastasis (BM)-prone. We determined the impact of this hallmark, along with EGFR subtype and generation of tyrosine kinase inhibitor (TKI) tre
Externí odkaz:
https://doaj.org/article/bce3fbab037c45f29c24a461f2f07a28
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
Autor:
Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang, Jia-Shiuan Ju, Chi-Hsien Huang, Chin-Chou Wang, How-Wen Ko, Fu-Tsai Chung, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Substitution of methionine for threonine at codon 790 (T790M) of epidermal growth factor receptor (EGFR) represents the major mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in EGFR -mutant non-small-cell lung cancer. We
Externí odkaz:
https://doaj.org/article/cb59f58b72a54d5aa11a70e91bdabd7a
Autor:
Tzu-Hsuan Chiu, Pi-Hung Tung, Chi-Hsien Huang, Jia-Shiuan Ju, Allen Chung-Cheng Huang, Chin-Chou Wang, Ho-Wen Ko, Ping-Chih Hsu, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) patients was lacking. 310 patients of advanced NSCLC with common EGFR mutati
Externí odkaz:
https://doaj.org/article/17eff21402b64752921f6d7b503a59e8
Autor:
Chih-Hsi Scott Kuo, Pi-Hung Tung, Allen Chung-Cheng Huang, Chin-Chou Wang, John Wen-Cheng Chang, Chien-Ying Liu, Fu-Tsai Chung, Yueh-Fu Fang, Yi-Ke Guo, Cheng-Ta Yang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
Abstract Background Crizotinib is the approved treatment for advanced non-small cell lung cancers (NSCLCs) of anaplastic lymphoma kinase (ALK) fusion. Failure of crizotinib treatment frequently involves drug intolerance or resistance. Comparison of u
Externí odkaz:
https://doaj.org/article/eeafe09ab5ed4f38b366519b8f261d8c
Publikováno v:
Data, Vol 8, Iss 3, p 61 (2023)
Temporal knowledge graphs can be used to represent the current state of the world and, as daily events happen, the need to update the temporal knowledge graph, in order to stay consistent with the state of the world, becomes very important. However,
Externí odkaz:
https://doaj.org/article/d4c4146faa1a429297d6cf3837fcace7
Autor:
Chia‐Hsun Chu, Tzu‐Hsuan Chiu, Chin‐Chou Wang, Wen‐Chen Chang, Allen Chung‐Cheng Huang, Chien‐Ying Liu, Chih‐Liang Wang, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi S. Kuo, Cheng‐Ta Yang
Publikováno v:
Thoracic Cancer, Vol 11, Iss 6, Pp 1541-1549 (2020)
Background Treatment for stage III non‐small cell lung cancer (NSCLC) of unresectable disease mainly involves concurrent chemoradiation (CRT). Post‐CRT consolidation treatment with durvalumab is a major therapeutic advance that provides survival
Externí odkaz:
https://doaj.org/article/521f162d13944edf8763192c7fba81bd
Autor:
Shih‐Hao Huang, Allen Chung‐Cheng Huang, Chin‐Chou Wang, Wen‐Chen Chang, Chien‐Ying Liu, Stelios Pavlidis, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
Publikováno v:
Thoracic Cancer, Vol 10, Iss 12, Pp 2274-2281 (2019)
Background Approximately 3%–5% of lung adenocarcinoma is driven by anaplastic lymphoma kinase (ALK) fusion oncogene, whose activity can be suppressed by multiple ALK inhibitors. Crizotinib and ceritinib have demonstrated superior efficacy to platin
Externí odkaz:
https://doaj.org/article/14888838e0be4033bf09e21936ae250a
Autor:
Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, Pi-Hung Tung, Chin-Chou Wang, Chien-Ying Liu, Fu-Tsai Chung, Yueh-Fu Fang, Yi-Ke Guo, Chih-Hsi Scott Kuo, Cheng-Ta Yang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: There are limited comparisons of first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in large, real-world cohorts of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor ( EGFR ) mutations. Met
Externí odkaz:
https://doaj.org/article/763e57c256f446a5b609a81341cda010
Publikováno v:
Molecular Systems Biology, Vol 17, Iss 6, Pp n/a-n/a (2021)
Abstract Transposable elements (TEs) are widespread across eukaryotic genomes, yet their content varies widely between different species. Factors shaping the diversity of TEs are poorly understood. Understanding the evolution of TEs is difficult beca
Externí odkaz:
https://doaj.org/article/0f31713da41040b48b1bd49e8bf86d2e
Publikováno v:
Big Data Mining and Analytics, Vol 2, Iss 2, Pp 83-91 (2019)
In this paper, we suggest a new methodology which combines Neural Networks (NN) into Data Assimilation (DA). Focusing on the structural model uncertainty, we propose a framework for integration NN with the physical models by DA algorithms, to improve
Externí odkaz:
https://doaj.org/article/5b3da76349d74dfbb5a5501b2b53b0a4